ELRIG Announces Drug Discovery 2015 Programme
News Jun 25, 2015
ELRIG’s Drug Discovery event will feature world class speakers presenting on the latest challenges and advances in early stage and translational drug discovery, and provides scientists an excellent opportunity to network throughout the two days.
As well as the programme of more than 50 scientific presentations, the 2015 event will feature poster sessions, Core Technologies Workshops, SLAS Authors Workshops, an exhibition area with around 100 vendor booths, as well as an Innovation Zone for new and exciting emerging companies and technologies, and a Media Area and Careers Zone.
This year sees the addition of two new scientific sessions, ‘Cell & Gene Therapy’ and ‘New Biologic Drugs & Technologies’, as well as: ‘Innovation in Assay Development & Screening’; ‘Metabolic & Cardiovascular Drug Discovery’; ‘Chemistry Innovation in Lead Discovery’; ‘Target Identification & Validation’; ‘Phenotypic Discovery & Cell Imaging’; and ‘Oncology Drug Targets’.
The Core Technologies Workshops provide a more informal, interactive environment in which to discuss key issues and future directions, coordinated by leaders in their fields. This year the workshops will focus on: ‘Enzymology Applications in Drug Discovery’; ‘Protein:Protein Interaction in Drug Discovery’; ‘Ant-Infectives’; and ‘Future of HTS’.
Plenary keynote speakers at this year’s event are David Thomas, Traffick Therapeutiques, and Professor Tracy Hussell, Manchester Collaborative Centre for Inflammation Research. An interview with Prof. Hussell can be found here. Keynote speakers for the four session tracks include: Stephen Rees, AstraZeneca; Dr Chris Torrance, PhoreMost Ltd; Gerard Drewes, Cellzome; Stefano Pluchino , Wellcome Trust-MRC Stem Cell Institute, University of Cambridge (UK); Chas Bountra, SGC, University of Oxford; Philipp Holliger , MRC Laboratory of Molecular Biology; Damian Young, Baylor College of Medicine; and Daniel P. Kelly, Sanford-Burnham Medical Research Institute at Lake Nona.
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE